{ "schemaVersion": "deck-intelligence.v1", "id": "019dd923-622c-750b-8b97-e9d223c0ba42", "slug": "88a4417a0cf1", "title": "Apellis Pharmaceuticals (APLS)", "subtitle": "Citron Research · 2023-11", "author": "Citron Research", "date": "2023-11-06 00:00:00", "pageCount": 13, "kind": "research-note", "orientation": "portrait", "aspectRatio": 0.77295077, "targetCompany": "Apellis Pharmaceuticals", "targetTicker": "APLS", "document": { "id": "019dd923-622c-750b-8b97-e9d223c0ba42", "slug": "88a4417a0cf1", "title": "Apellis Pharmaceuticals (APLS)", "rawTitle": "Citron Reports on Apellis Pharmaceuticals", "authorId": "52_Citron_Research", "authorName": "Citron Research", "authorDisplay": "Citron Research", "kind": { "slug": "research-note", "label": "Research note" }, "sourceType": { "slug": "short_seller", "label": "Short seller" }, "fileName": "2023-11-Citron-Reports-on-Apellis-Pharmaceuticals.pdf", "sourceUrl": "http://www.citronresearch.com", "sourceDate": "2023-11-06 00:00:00", "presentationDate": "2023-11-06 00:00:00", "ingestedAt": "2026-04-22 20:20:45+00", "status": "ready", "pageCount": 13, "orientation": "portrait", "aspectRatio": 0.77295077, "targetCompany": "Apellis Pharmaceuticals", "targetTicker": "APLS", "metadata": { "local_root": "/tmp/legacy-images/88a4417a0cf1", "activist_firm": "Citron Research", "origin_corpus": "contrarian", "extraction_seconds": 97.98259091377258 } }, "coverage": { "pageCount": 13, "pagesIndexed": 13, "pagesWithImages": 13, "pagesWithMetadata": 13, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 75, "chartCount": 2, "metricSlides": 0, "toolMatches": 3, "documentToolMatches": 3, "frameworkMatches": 5, "arcMatches": 1, "beatMatches": 3, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": true, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null, "categoryName": "Booker's 7 Plots", "categorySlug": "booker-s-7-plots" }, "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "evidence": "The document follows a narrative of presenting a problem (Syfovre's complications), building tension (through critical reviews and data revelations), and concluding with a call to action (expecting a FDA warning letter).", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 21:59:16.506217+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 5, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null, "categoryName": "Booker's 7 Plots", "categorySlug": "booker-s-7-plots" }, "from": 2, "name": "The Monster", "beatId": "35b7911a-b113-4112-9253-57c0fd4ab885", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Monster", "slug": "overcoming-monster-the-monster", "status": "active", "canonId": "019dd9b8-3ba3-70b3-85b6-6dc1928acd40", "version": 1, "description": null }, "evidence": "The document presents Syfovre's complications as the central problem to be addressed.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Hook", "slug": "hook", "status": "active", "canonId": "019dd9b8-01a6-7328-bff2-b22eb40b3ea5", "version": 1, "description": "The opener — a deliberate move to earn attention before any argument. Used by AIDA, Monroes, Pixar Pitch, Overcoming the Monster." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 8, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null, "categoryName": "Booker's 7 Plots", "categorySlug": "booker-s-7-plots" }, "from": 6, "name": "The Struggle", "beatId": "ad97bdfc-9557-49c8-b876-02597086cd90", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Struggle", "slug": "overcoming-monster-the-struggle", "status": "active", "canonId": "019dd9b8-3d24-71b1-9262-9a8f9850fda3", "version": 1, "description": null }, "evidence": "Citron Research presents various critiques and data to challenge Apellis' claims.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 13, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null, "categoryName": "Booker's 7 Plots", "categorySlug": "booker-s-7-plots" }, "from": 12, "name": "The Victory", "beatId": "00cd5a6d-dcee-4fba-90ee-27fb59ffa2f9", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Victory", "slug": "overcoming-monster-the-victory", "status": "active", "canonId": "019dd9b8-3dbe-71b9-b5a9-7191b5f8782b", "version": 1, "description": null }, "evidence": "Citron Research concludes with an expectation of regulatory action, framing it as a victory for their critical stance.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 8, "loop": { "name": "05_the_reveal", "slug": "05-the-reveal", "status": "active", "bestFor": "Product launches, strategic pivots, unexpected findings", "canonId": "019dd956-67e8-77bc-a867-02c2b36370bd", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Setup the Question -> Build Suspense -> The Big Reveal", "description": "Build mystery and anticipation, then deliver a surprising or powerful conclusion", "familyLabel": null, "categoryName": "Narrative", "categorySlug": "narrative" }, "matchId": "777dcc74-3c64-4bf9-add4-30634d953462", "evidence": "The document reveals at least 12 cases of vasculitis, contrary to Apellis' claims.", "position": 0, "objective": "What are the actual cases of vasculitis associated with Syfovre?", "confidence": 0.7, "extraction": { "at": "2026-07-16 21:59:16.667257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "CEO quote contradiction", "slug": "ceo-quote-contradiction", "status": "active", "bestFor": "When management credibility is the lever", "canonId": "019dd9e1-52e9-717f-8454-93e627563ed6", "version": 1, "bodyDocId": "019dd9a1-8296-720d-8f51-da76937f9415", "description": "You reproduce management's own words — verbatim, with source and date — and\nthen place them next to the outcome that contradicts them. The CEO built\nthe rope; you put it around their own neck.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "document", "agents": null, "matchId": "5062f1a9-1048-4d6d-a59e-5ab40962fa6d", "evidence": null, "pageRefs": null, "priority": null, "whenToUse": "When management credibility is the lever", "confidence": null, "extraction": { "at": "2026-04-29 12:07:50.005477+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": null, "whyItWorks": "- **Maximum credibility**: no adjective you could write is as damning as the\n target's own prior statement.\n- **No rebuttal path**: management can't argue they didn't say it.\n- **It forces accountability onto a person**, not an institution — even if\n you aren't explicitly naming a villain elsewhere.\n- **Reporters amplify it**. A CEO-quote-contradiction slide is quotable,\n which means it lands in WSJ/FT/Bloomberg coverage.", "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Villain naming", "slug": "villain-naming", "status": "active", "bestFor": "When governance or specific decisions are the core thesis", "canonId": "019dd9e1-55a4-74db-9314-0ced4cd46cd2", "version": 1, "bodyDocId": "019dd9a1-88f1-72ad-8f4e-56ec29d7b369", "description": "You identify a **specific person** responsible for the target's underperformance\nor the behaviour you want changed — and name them. Not \"management\" or \"the\nboard\". A named executive or director with a specific failure attributable to\nthem.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "document", "agents": null, "matchId": "4510fc57-3b38-4fd5-ab0b-af5a09064388", "evidence": "Cedric Francois (CEO, Apellis Pharmaceuticals)", "pageRefs": null, "priority": null, "whenToUse": "When governance or specific decisions are the core thesis", "confidence": null, "extraction": { "at": "2026-04-29 12:07:50.005477+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": null, "whyItWorks": "- **Accountability needs a face.** Voters (shareholders, regulators,\n journalists) act faster against people than institutions.\n- **Credibility rises with specificity.** \"The CFO has repeatedly missed\n guidance\" > \"Management has missed guidance\".\n- It **pre-empts evasion**. An individual can be removed; an abstraction\n cannot.\n- It **forces the target to respond personally** — and their defensive\n response usually generates more attention for your thesis.", "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Villain slide", "slug": "villain-slide", "status": "active", "bestFor": "In activist decks where the personality matters", "canonId": "019dd9e1-518c-7404-976a-5be5a517b659", "version": 1, "bodyDocId": null, "description": "A dedicated slide presenting the named villain visually", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "document", "agents": null, "matchId": "923c3bd0-744f-44eb-a543-afdac900b992", "evidence": null, "pageRefs": null, "priority": null, "whenToUse": "In activist decks where the personality matters", "confidence": null, "extraction": { "at": "2026-04-29 12:07:50.005477+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": null, "whyItWorks": "Makes the antagonist concrete", "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "b36f155a-4390-4ee0-8866-cb40c06bce15", "evidence": "Uses Dr. Richard Spaide's credentials to challenge Apellis's claims.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:45:37.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "frameworkName": "authority-citation" }, { "matchId": "2fc0cb87-8a42-4d1b-b877-49eac59e1125", "evidence": "Uses the Moneyball quote to frame the drug's performance.", "framework": null, "confidence": 0.85, "extraction": { "at": "2026-05-02 20:45:37.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "frameworkName": "metaphor-analogy" }, { "matchId": "4e31c579-c621-4aa8-96f5-cc7e31fa5415", "evidence": "Citing Dr. Suber Huang, former President of ASRS, to validate the research findings.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:45:37.803+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "authority-citation" }, { "matchId": "9ccf65e3-78f1-4703-8507-c6cb3a8ac444", "evidence": "The slide explicitly questions 'Securities Fraud?' and attempts to expose a contradiction between CEO statements and reported safety data.", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 20:45:39.428+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "fraud-exposure" }, { "matchId": "4c4a9ac3-6f1b-4614-982e-522c8a5eefa4", "evidence": "Contradicting CEO claims with external data to allege securities fraud", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:45:37.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "fraud-exposure" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": { "tone": "adversarial", "notes": "Short-seller research note structured as a Word-style memo with embedded screenshots from AAO 2023 presentations (Spaide, Wolfe/Johnson), a borrowed Jefferies Beovu volume chart, and FDA FOIA adverse-event tables. No named individual author — issued under the Citron Research brand. Core rhetorical moves: (1) 83% AAO audience vote used as a single devastating statistic; (2) FOIA-vs-CEO-quote contradiction to pivot from safety critique to securities-fraud allegation; (3) Beovu analogy as the implicit price-path template. No explicit price target or sum-of-parts valuation; the deck is catalyst-driven (FDA warning, litigation) rather than valuation-driven. Closes with a sarcastic 'Did somebody say 83%???' callback echoing the AAO vote.", "kpisCited": [ { "detail": "83% against, 17% in favor (audience of ophthalmologists who financially benefit from administering it)", "metric": "AAO 2023 panel vote on Syfovre acceptability" }, { "detail": "1 in 28 Syfovre injections resulted in halted treatment; 5 of 137 injections across 96 eyes", "metric": "Wolfe Eye Clinic complication rate" }, { "detail": "12+ cases reported in the last month vs CEO's claim of one September case", "metric": "FOIA vasculitis reports" }, { "detail": "$20,000 to $30,000 in Medicare reimbursements per patient per year", "metric": "Annual cost of Syfovre" }, { "detail": "~20% likelihood of a patient developing Wet AMD", "metric": "Wet AMD risk from Syfovre (per Dr. Wykoff)" }, { "detail": "Approaches zero, may be less than zero given no visual improvement and injection risks", "metric": "QALYs for Syfovre (per Dr. Spaide)" }, { "detail": "Top 0.01% per Ioannidis analysis of 7M scientists; 400+ articles, 50 book chapters, 9 books", "metric": "Dr. Spaide scientific ranking" } ], "closingAsk": "Investors should exit Apellis in anticipation of an FDA warning label, litigation, and a Beovu-style collapse in Syfovre physician adoption.", "extraction": { "at": "2026-04-22 20:20:45+00", "model": "unknown-legacy", "runId": null, "seconds": 97.98259, "promptVersion": null }, "scqaReward": "Citron implies APLS will follow Novartis's Beovu, whose physician usage collapsed permanently after ASRS vasculitis warnings — a trajectory that would inflict heavy damage on Apellis's financials and share price.", "thesisTypes": [ "fraud_exposure" ], "top3Reasons": [ "AAO 2023 ophthalmologists voted 83%-17% that Syfovre is not an acceptable therapy", "Wolfe Eye Clinic observed complications in 1 of 28 Syfovre injections, urging a warning or pause", "FOIA reveals 12+ vasculitis reports vs CEO's claim of a single September case — potential securities fraud" ], "scqaSituation": "Apellis launched Syfovre in early 2023 as the first FDA-approved treatment for Geographic Atrophy, bypassing an FDA advisory committee and generating Wall Street excitement aided by a Henry Winkler celebrity marketing campaign.", "thesisSummary": "Apellis Pharmaceuticals' Syfovre — the first FDA-approved Geographic Atrophy treatment, launched in 2023 without an FDA advisory committee and marketed by Henry 'The Fonz' Winkler — faces mounting clinical and safety problems that Citron argues will trigger a warning label or pause. At the November 2023 American Academy of Ophthalmology meeting, panelists voted 83% against Syfovre being an 'acceptable' therapy, with top vitreoretinal surgeon Dr. Richard Spaide citing QALYs approaching zero and the Wolfe Eye Clinic reporting complications in 1 of 28 injections. A Freedom of Information Act request reveals at least 12 vasculitis cases in the past month, contradicting CEO Cedric Francois's claim of a lone September case and raising potential securities-fraud exposure. Citron draws an explicit analogy to Novartis's Beovu, whose physician usage collapsed after similar ASRS vasculitis warnings, implying substantial downside for APLS.", "primaryDemands": [ "FDA issue a warning label on Syfovre or pause the drug", "Regulators investigate CEO Cedric Francois's disclosures for possible securities fraud", "Shareholders reassess Apellis given likelihood of Beovu-style physician abandonment" ], "scqaResolution": "Citron calls for the FDA to impose a warning label or pause Syfovre, and flags CEO Cedric Francois's understatement of vasculitis cases on the Q3 earnings call as potential securities fraud warranting regulator review.", "thesisOneLiner": "Citron shorts Apellis, arguing its new Geographic Atrophy drug Syfovre faces an imminent FDA warning as AAO ophthalmologists reject it 83%-17% and vasculitis cases mount.", "precedentsCited": [ "Novartis Beovu (ASRS vasculitis warnings triggered physician abandonment, Feb 2020)", "Henry Winkler / One Reverse Mortgages shutdown ('Fonzi Scheme')" ], "scqaComplication": "Real-world vasculitis complications are accumulating: Wolfe Eye Clinic saw 1 in 28 injections cause harm, the AAO 2023 audience voted 83% against acceptability, and FOIA filings contradict the CEO's claim of a single case.", "narrativeInterest": 4, "notableSlidePages": [ 1, 2, 5, 7, 8, 11 ], "peerCompaniesCited": [ "Novartis (Beovu)" ], "valuationFrameworks": [ "not_shown" ], "visualCraftInterest": 2 }, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "tension", "title": "Includes a testimonial/marketing image from Apellis featuring Henry Winkler.", "function": "frame_problem", "imagePath": "https://imgproxy.kitesheet.com/Mmja_6VvazvEnEMQ9QArk9HtH-S_v08L9yygDCJhINk/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84OGE0NDE3YTBjZjEvcDAwMS5wbmc", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 8, "textChars": 1105, "nDataPoints": 1, "notes": "Includes a testimonial/marketing image from Apellis featuring Henry Winkler.", "elementsJson": [ "headline_text", "subtitle_text", "paragraph", "photo", "quote_block" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:36.554+00", "seconds": 2.81, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/1", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-1", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Happy Days Are OVER for Apellis, as the Experts Give a Thumbs Down to Syfovre. Citron Expects FDA Warning Letter.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:20:57+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd4-cc93d867a503", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.3, "y": 0.48 }, "kind": "image", "text": "Henry Winkler advertisement for Apellis", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:36.554+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f04a09ad-331a-4883-88dd-19dcf507f281", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.78, "x": 0.11, "y": 0.67 }, "kind": "paragraph", "text": "Four months after releasing Syfovre, the drama began. Apellis Pharmaceuticals was hit with reports from the ASRS of retinal vasculitis as a side effect, causing their stock to drop.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:36.554+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35714d86-078c-4f9d-9a44-c8c2663fde4d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.78, "x": 0.11, "y": 0.21 }, "kind": "paragraph", "text": "Citron Research was committed to ensuring that its return to short selling was marked by a report that would not only hinge on valuation concerns but also spotlight a company whose activities could be detrimental to the public interest.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:36.554+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d5c8c6a-f43c-4ff7-9c80-948f124bbb4e", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.78, "x": 0.11, "y": 0.78 }, "kind": "paragraph", "text": "The following month Favus Research initiated a report claiming the Apellis trials didn't sufficiently report 14 cases of retinal vasculitis, an inflammatory condition that kills blood vessels in patients receiving the therapy.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:36.554+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9b54dbe4-e8a2-414a-aee0-d8c3b8df06b2", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "\"If I started seeing changes, I'd carry my car to the eye doctor's office. That's how on top of your vision you have to be.\" — Henry Winkler", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:20:57+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd4-d0d1decb7a84", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.78, "x": 0.11, "y": 0.15 }, "kind": "title", "text": "Happy Days Are OVER for Apellis, as the Experts Give a Thumbs Down to Syfovre. Citron Expects FDA Warning Letter.", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:36.554+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cfc82f20-2231-439a-b8b7-f39dfa6d737e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.78, "x": 0.11, "y": 0.11 }, "kind": "title", "text": "Citron Research Reports on Apellis Pharmaceuticals (APLS)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:36.554+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b32f4af9-2502-48c5-b525-f1cabd3a009d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "thumbSrc": "https://imgproxy.kitesheet.com/wsXpOoTN90w7OABeUlU1gF3p7I0wSwwGrsj704WFn2w/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84OGE0NDE3YTBjZjEvcDAwMS5wbmc", "imagePathAlt": "https://imgproxy.kitesheet.com/rXUOR0OVxFKl-V28oNxbX2At6IOUdHtI7IYe5ndnKwk/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84OGE0NDE3YTBjZjEvcDAwMS5qcGc", "thumbSrcAlt": "https://imgproxy.kitesheet.com/lf3end9R1s47ivHhi9695o9NX5gHpEhH4g6j0HXtBDg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84OGE0NDE3YTBjZjEvcDAwMS5qcGc" }, { "page": 2, "type": "tension", "title": "The slide uses a 'jumped the shark' idiom to frame the drug's clinical reception as having peaked and begun a decline in credibility.", "function": "expose_contradiction", "rawType": "research-note", "block": null, "metadata": { "slideType": "research-note", "slideTypeCanon": null, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 8, "textChars": 941, "nDataPoints": 0, "notes": "The slide uses a 'jumped the shark' idiom to frame the drug's clinical reception as having peaked and begun a decline in credibility.", "elementsJson": [ "headline_text", "paragraph", "screenshot", "callout_box" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:41.324+00", "seconds": 7.429, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/2", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-2", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Friday, November 3, 2023 is the day Syfovre \"Jumped the Shark\"", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:04+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd7-eb1c41edf16d", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.39, "x": 0.305, "y": 0.258 }, "kind": "image", "text": "AAO 2023 logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:41.324+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ea71042-4fb5-484a-ab55-5a385a02df8b", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.6, "x": 0.2, "y": 0.535 }, "kind": "image", "text": "Current Complement Inhibition Therapy for Geographic Atrophy Is Acceptable: 1. Pro (Usha Chakravarthy PhD MBBS) 2. Con (Richard F Spaide MD)", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:41.324+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9c8be4b-cb65-4b7a-89b8-a338935b71c4", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.77, "x": 0.118, "y": 0.403 }, "kind": "paragraph", "text": "This past Friday was the first meeting of the AAO since the approval of Syfovre, there was a panel debate on Syfovre, questioning whether the treatment is \"acceptable\".", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:41.324+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a6411ca-1ae2-47ba-99d1-3289d03e1460", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.77, "x": 0.118, "y": 0.738 }, "kind": "paragraph", "text": "The PRO - Dr. Chakravarthy, a respected academic, described the new treatment as a progressive development in the quest for effective therapies. She emphasized the ongoing necessity for innovation and investment in addressing the disease.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:41.324+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9ae4390d-fa2e-4ce7-9016-18b2c80ecacc", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.77, "x": 0.118, "y": 0.163 }, "kind": "paragraph", "text": "Last week was the first meeting of the American Academy of Ophthalmology in San Francisco since the approval of Syfovre. The Academy has the world's largest association of eye physicians and surgeons with more than 32,000 doctors.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:41.324+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7c397fc-ac5f-4fac-9a10-475973be20b4", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.118, "y": 0.353 }, "kind": "title", "text": "Friday, November 3, 2023 is the day Syfovre \"Jumped the Shark\"", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:41.324+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af08eb0c-e01d-48c0-8056-2382eab79cf2", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.45, "x": 0.118, "y": 0.113 }, "kind": "title", "text": "Everything Has Now Changed!!", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:41.324+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b792b1f2-21f0-4e14-93e8-3a4fc1ea84e3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 2, "name": "The Monster", "beatId": "35b7911a-b113-4112-9253-57c0fd4ab885", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Monster", "slug": "overcoming-monster-the-monster", "status": "active", "canonId": "019dd9b8-3ba3-70b3-85b6-6dc1928acd40", "version": 1, "description": null }, "evidence": "The document presents Syfovre's complications as the central problem to be addressed.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Hook", "slug": "hook", "status": "active", "canonId": "019dd9b8-01a6-7328-bff2-b22eb40b3ea5", "version": 1, "description": "The opener — a deliberate move to earn attention before any argument. Used by AIDA, Monroes, Pixar Pitch, Overcoming the Monster." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 3, "type": "tension", "title": "Uses a 'Moneyball' quote to frame the argument against the drug's clinical performance.", "function": "expose_contradiction", "rawType": "villain_critique", "block": null, "metadata": { "slideType": "villain_critique", "slideTypeCanon": { "name": "Villain critique", "slug": "villain_critique", "status": "active", "canonId": "019de52d-10bc-7136-bf20-09de59d17447", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "balanced", "densityScore": 39, "componentCount": 7, "textChars": 760, "nDataPoints": 0, "notes": "Uses a 'Moneyball' quote to frame the argument against the drug's clinical performance.", "elementsJson": [ "screenshot", "bullet_list", "paragraph", "quote_block" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:37.748+00", "seconds": 3.575, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/3", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-3", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Dr Spaide completely discredits the questionable studies of Syfovre in relation to real life practice, but more importantly he ALSO discredits the efficacy of the treatment quoting the classic movie line.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:20:58+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd5-0e723d218971", "parentComponentId": null }, { "bbox": { "h": 0.176, "w": 0.603, "x": 0.197, "y": 0.706 }, "kind": "image", "text": "Screenshot of presentation slide with Moneyball quote", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06387757-c324-4b18-8e29-d2eb659a3ba7", "parentComponentId": null }, { "bbox": { "h": 0.215, "w": 0.543, "x": 0.227, "y": 0.1 }, "kind": "image", "text": "Screenshot of AAQ 2023 presentation slide", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "babe4d65-26b3-407a-87e5-b807929118f8", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.72, "x": 0.14, "y": 0.458 }, "kind": "list", "text": "Credentials of Dr. Richard Spaide including awards, publication count, and editorial roles.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "17d624a5-9c1a-4cf3-a3db-dd029a252884", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.78, "x": 0.11, "y": 0.625 }, "kind": "paragraph", "text": "Dr Spaide completely discredits the questionable studies of Syfovre in relation to real life practice, but more importantly he ALSO discredits the efficacy of the treatment quoting the classic movie line.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8b29618-d6ad-486b-9776-345061cd85a7", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "\"If he's such a good hitter, why doesn't he hit good?\" — Billy Beane, Moneyball", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:20:58+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd5-104371911531", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.78, "x": 0.11, "y": 0.37 }, "kind": "title", "text": "The Con- Dr. Richard Spaide - Apellis Shareholders - Do you know more than this guy?????", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a2a3a8b7-70e3-454c-aaf0-ac86e91a9d86", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b36f155a-4390-4ee0-8866-cb40c06bce15", "evidence": "Uses Dr. Richard Spaide's credentials to challenge Apellis's claims.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:45:37.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "frameworkName": "authority-citation" }, { "matchId": "2fc0cb87-8a42-4d1b-b877-49eac59e1125", "evidence": "Uses the Moneyball quote to frame the drug's performance.", "framework": null, "confidence": 0.85, "extraction": { "at": "2026-05-02 20:45:37.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "frameworkName": "metaphor-analogy" } ], "arcBeats": [ { "to": 5, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 2, "name": "The Monster", "beatId": "35b7911a-b113-4112-9253-57c0fd4ab885", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Monster", "slug": "overcoming-monster-the-monster", "status": "active", "canonId": "019dd9b8-3ba3-70b3-85b6-6dc1928acd40", "version": 1, "description": null }, "evidence": "The document presents Syfovre's complications as the central problem to be addressed.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Hook", "slug": "hook", "status": "active", "canonId": "019dd9b8-01a6-7328-bff2-b22eb40b3ea5", "version": 1, "description": "The opener — a deliberate move to earn attention before any argument. Used by AIDA, Monroes, Pixar Pitch, Overcoming the Monster." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 4, "type": "tension", "title": "The slide uses screenshots of a presentation to illustrate the doctor's arguments, which Citron then undermines by pointing out financial incentives.", "function": "expose_contradiction", "rawType": "expose_contradiction", "block": null, "metadata": { "slideType": "expose_contradiction", "slideTypeCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-124c-75aa-984a-0a3d0d8fc8df", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "balanced", "densityScore": 28, "componentCount": 5, "textChars": 839, "nDataPoints": 0, "notes": "The slide uses screenshots of a presentation to illustrate the doctor's arguments, which Citron then undermines by pointing out financial incentives.", "elementsJson": [ "paragraph", "screenshot" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:42.496+00", "seconds": 7.66, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/4", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-4", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "What would the QALYs be for a treatment that causes no improvement in visual function but requires frequent injections into the eye?", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:20:59+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd5-621be228f9c5", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.5, "x": 0.25, "y": 0.26 }, "kind": "image", "text": "Screenshots of presentation slides regarding Pegacetacoplan, QALYs, and the bigger picture.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:42.496+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a6d6632-2be4-4625-9835-4f64252a3e45", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.78, "x": 0.11, "y": 0.82 }, "kind": "paragraph", "text": "After the conclusion of both presentations, the audience cast their votes, and the outcome was a resoundingly unanimous decision. This is from an audience who would financially benefit from voting Pro.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:42.496+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6b4fc46d-79b0-4f0e-93aa-472cefd40632", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.78, "x": 0.11, "y": 0.15 }, "kind": "paragraph", "text": "Note these harsh criticisms come from a doctor whose practice stands to profit significantly from Medicare reimbursements for administering the costly Syfovre, which ranges from $20,000 to $30,000 annually, He sharply criticizes the use of government funds for a drug that just slows the progression of retina lesions in an elderly patient. Syfovre does not make you see better.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:42.496+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c3ccbe79-1448-4381-9829-3d5a3225c750", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "QALY approaches 0, may be less than 0", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:20:59+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd5-653121708137", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 2, "name": "The Monster", "beatId": "35b7911a-b113-4112-9253-57c0fd4ab885", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Monster", "slug": "overcoming-monster-the-monster", "status": "active", "canonId": "019dd9b8-3ba3-70b3-85b6-6dc1928acd40", "version": 1, "description": null }, "evidence": "The document presents Syfovre's complications as the central problem to be addressed.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Hook", "slug": "hook", "status": "active", "canonId": "019dd9b8-01a6-7328-bff2-b22eb40b3ea5", "version": 1, "description": "The opener — a deliberate move to earn attention before any argument. Used by AIDA, Monroes, Pixar Pitch, Overcoming the Monster." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "tension", "title": "Includes a screenshot of a presentation slide from Dr. William Johnson and a donut chart showing 83% vs 17% sentiment.", "function": "expose_contradiction", "rawType": "expose_contradiction", "block": null, "metadata": { "slideType": "expose_contradiction", "slideTypeCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-124c-75aa-984a-0a3d0d8fc8df", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 8, "textChars": 787, "nDataPoints": 3, "notes": "Includes a screenshot of a presentation slide from Dr. William Johnson and a donut chart showing 83% vs 17% sentiment.", "elementsJson": [ "donut_chart", "paragraph", "screenshot" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:43.015+00", "seconds": 7.776, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/5", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-5", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Wolfe Clinic recognized complications in 1 in 28 per injection. His conclusion that Syfovre should immediately get a warning label or get paused altogether.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:03+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd7-1719631d1276", "parentComponentId": null }, { "bbox": { "h": 0.336, "w": 0.536, "x": 0.232, "y": 0.1 }, "kind": "chart", "text": "Current Complement Inhibition Therapy for Geographic Atrophy Is Acceptable: 83% Pro, 17% Con", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Donut chart", "slug": "donut", "status": "active", "canonId": "019de52d-0006-752c-9528-0fef476b8004", "version": 1, "description": null }, "framework": null }, "subkind": "donut", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:43.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49cb73f3-152c-41f8-bc3e-d42e37a21e97", "parentComponentId": null }, { "bbox": { "h": 0.212, "w": 0.733, "x": 0.133, "y": 0.628 }, "kind": "image", "text": "Introduction slide from Dr. William Johnson's presentation", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:43.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "abf0066c-fcd9-44ac-838b-af414a4654db", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "ophthalmologist sentiment: 83%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:03+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd7-1ebd1b6fa2ff", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.764, "x": 0.118, "y": 0.437 }, "kind": "paragraph", "text": "In a presentation later in the day entitled “Late Breaking Developments” Dr. William Johnson of the Wolfe Eye Clinic presented a critical analysis of Syfovre entitled, “Syfovre Initial Complication Experience”", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:43.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5aa20939-5c62-4523-a8bc-2f3ebfe1ccc5", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.764, "x": 0.118, "y": 0.87 }, "kind": "paragraph", "text": "Wolfe Clinic recognized complications in 1 in 28 per injection. His conclusion that Syfovre should immediately get a warning label or get paused altogether.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:43.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb8ecab3-5a58-4a23-b4ae-33e5a5339e08", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Syfovre Initial Complication Experience — Dr. William Johnson", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:03+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd7-1af61ce8ca16", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.445, "x": 0.118, "y": 0.39 }, "kind": "title", "text": "But Wait....It Gets Worse", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:43.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4ff7bfc-bc0a-4f79-9f65-b8ca4dbf9ad5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 2, "name": "The Monster", "beatId": "35b7911a-b113-4112-9253-57c0fd4ab885", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Monster", "slug": "overcoming-monster-the-monster", "status": "active", "canonId": "019dd9b8-3ba3-70b3-85b6-6dc1928acd40", "version": 1, "description": null }, "evidence": "The document presents Syfovre's complications as the central problem to be addressed.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Hook", "slug": "hook", "status": "active", "canonId": "019dd9b8-01a6-7328-bff2-b22eb40b3ea5", "version": 1, "description": "The opener — a deliberate move to earn attention before any argument. Used by AIDA, Monroes, Pixar Pitch, Overcoming the Monster." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "evidence", "title": "The slide contains two embedded screenshots of presentation slides (Results and Conclusions) and a testimonial from Dr. Suber Huang.", "function": "illustrate_case", "rawType": "testimonial", "block": null, "metadata": { "slideType": "testimonial", "slideTypeCanon": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52d-0a2d-7782-8a48-7e84df92cc97", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 7, "textChars": 587, "nDataPoints": 6, "notes": "The slide contains two embedded screenshots of presentation slides (Results and Conclusions) and a testimonial from Dr. Suber Huang.", "elementsJson": [ "screenshot", "paragraph", "quote_block" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:37.803+00", "seconds": 2.484, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/6", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-6", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Treatment emergent events not described in pivotal trials can be quite alarming and can justify greater caution or a pause altogether", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:04+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd7-8547c8a36b9d", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.62, "x": 0.19, "y": 0.09 }, "kind": "image", "text": "Results slide from Dr. Johnson's presentation", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.803+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8aea8ca-8a60-4ec8-84be-caa99c2f0ed7", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.62, "x": 0.19, "y": 0.39 }, "kind": "image", "text": "Conclusions slide from Dr. Johnson's presentation", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.803+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bf9ce800-1096-415e-be55-5595b59f09f1", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.76, "x": 0.12, "y": 0.64 }, "kind": "paragraph", "text": "Dr. Johnson's presentation was so impactful that immediately after Dr. Suber Huang... commented", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.803+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54247915-2485-4b74-ab13-c7cffdfcb810", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.76, "x": 0.12, "y": 0.73 }, "kind": "quote", "text": "Kudos to your practice for putting together such a detailed summary of this unexpected and devastating complication.", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.803+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ebd111c2-cac1-4465-915f-fce74da0b0a8", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Kudos to your practice for putting together such a detailed summary of this unexpected and devastating complication. — Dr. Suber Huang", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:04+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd7-886fb0eccb37", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.28, "x": 0.12, "y": 0.04 }, "kind": "title", "text": "Citron Research", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.803+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "25060b3e-2f2d-4ed4-914c-c36449e737e0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4e31c579-c621-4aa8-96f5-cc7e31fa5415", "evidence": "Citing Dr. Suber Huang, former President of ASRS, to validate the research findings.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:45:37.803+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "authority-citation" } ], "arcBeats": [ { "to": 8, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 6, "name": "The Struggle", "beatId": "ad97bdfc-9557-49c8-b876-02597086cd90", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Struggle", "slug": "overcoming-monster-the-struggle", "status": "active", "canonId": "019dd9b8-3d24-71b1-9262-9a8f9850fda3", "version": 1, "description": null }, "evidence": "Citron Research presents various critiques and data to challenge Apellis' claims.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "tension", "title": "Includes a direct quote from an earnings call and a chart from a Jefferies analyst report.", "function": "expose_contradiction", "rawType": "expose_contradiction", "block": null, "metadata": { "slideType": "expose_contradiction", "slideTypeCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-124c-75aa-984a-0a3d0d8fc8df", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 8, "textChars": 1135, "nDataPoints": 30, "notes": "Includes a direct quote from an earnings call and a chart from a Jefferies analyst report.", "elementsJson": [ "paragraph", "screenshot", "quote_block" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:39.428+00", "seconds": 4.012, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/7", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-7", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Citron has reason to believe that CEO Cedric Francois is not being honest with Wall St. about the report cases of vasculitis.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:05+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd8-4ff0662fd290", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.734, "x": 0.133, "y": 0.309 }, "kind": "chart", "text": "Beovu Units Volume over time", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.428+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3832c0f7-6ad8-4697-a1dc-6cfaf739cd9c", "parentComponentId": null }, { "bbox": { "h": 0.055, "w": 0.764, "x": 0.118, "y": 0.148 }, "kind": "paragraph", "text": "Where there is smoke there must be fire and the metaphorical smoke in hallways of the AAO conference is obvious. The clinical trials are not matching the real-world profiles in safety and efficacy and the FDA should at a minimum put a warning label on Syfovre.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.428+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e9fb2f0f-d40f-4f42-afa2-463f9c862b39", "parentComponentId": null }, { "bbox": { "h": 0.065, "w": 0.764, "x": 0.118, "y": 0.84 }, "kind": "quote", "text": "So we're going to stop talking about individual cases because frankly that's not an effort that we think is fruitful. To put this in perspective, the last case of a patient with geographic atrophy that was reported to us with vasculitis is already from September first, right.", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.428+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "450ddcda-f83a-45fd-bc95-bbe978d2add0", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "So we're going to stop talking about individual cases because frankly that's not an effort that we think is fruitful. To put this in perspective, the last case of a patient with geographic atrophy that was reported to us with vasculitis is already from September first, right. — Cedric Francois", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:05+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd8-52e37b68d24c", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.55, "x": 0.118, "y": 0.91 }, "kind": "source-note", "text": "https://seekingalpha.com/article/4645993-apellis-pharmaceuticals-inc-apls-q3-2023-earnings-call-transcript", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.428+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86874529-71a8-4c46-8f9f-c3d8bd548990", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.315, "x": 0.118, "y": 0.108 }, "kind": "title", "text": "What happens next to Syfovre?", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.428+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f3da786-0fa9-4752-a623-22bda0e7a2f5", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.185, "x": 0.118, "y": 0.698 }, "kind": "title", "text": "Securities Fraud?", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.428+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3df2fbad-4285-424e-8e6e-86f102c2e27b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "9ccf65e3-78f1-4703-8507-c6cb3a8ac444", "evidence": "The slide explicitly questions 'Securities Fraud?' and attempts to expose a contradiction between CEO statements and reported safety data.", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 20:45:39.428+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "fraud-exposure" } ], "arcBeats": [ { "to": 8, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 6, "name": "The Struggle", "beatId": "ad97bdfc-9557-49c8-b876-02597086cd90", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Struggle", "slug": "overcoming-monster-the-struggle", "status": "active", "canonId": "019dd9b8-3d24-71b1-9262-9a8f9850fda3", "version": 1, "description": null }, "evidence": "Citron Research presents various critiques and data to challenge Apellis' claims.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "tension", "title": "The slide uses screenshots of FDA Adverse Event Reporting System documents to support the claim of securities fraud.", "function": "expose_contradiction", "rawType": "expose_contradiction", "block": null, "metadata": { "slideType": "expose_contradiction", "slideTypeCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-124c-75aa-984a-0a3d0d8fc8df", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "sparse", "densityScore": 22, "componentCount": 4, "textChars": 357, "nDataPoints": 12, "notes": "The slide uses screenshots of FDA Adverse Event Reporting System documents to support the claim of securities fraud.", "elementsJson": [ "paragraph", "screenshot" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:37.698+00", "seconds": 2.26, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/8", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-8", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Should this data be accurate, it raises the possibility of securities fraud on top of the reported adverse events from the past two months.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:01+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd6-3fd6a7e06bcd", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.64, "x": 0.18, "y": 0.23 }, "kind": "image", "text": "FDA Adverse Event Reporting System documents", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5ec7eee6-69c4-4243-b3a3-112e2ea0f319", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.76, "x": 0.118, "y": 0.088 }, "kind": "paragraph", "text": "Contrary to the CEO's claim of a solitary case of vasculitis, a Freedom of Information Act (FOIA) request reveals at least 12 cases reported in the last month.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0de481ed-69c2-421d-b889-59aa5f67f14f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.118, "y": 0.035 }, "kind": "title", "text": "Citron Research", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90703554-a2fa-4d9b-aa1d-305976ae6fcf", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4c4a9ac3-6f1b-4614-982e-522c8a5eefa4", "evidence": "Contradicting CEO claims with external data to allege securities fraud", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:45:37.698+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "fraud-exposure" } ], "arcBeats": [ { "to": 8, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 6, "name": "The Struggle", "beatId": "ad97bdfc-9557-49c8-b876-02597086cd90", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Struggle", "slug": "overcoming-monster-the-struggle", "status": "active", "canonId": "019dd9b8-3d24-71b1-9262-9a8f9850fda3", "version": 1, "description": null }, "evidence": "Citron Research presents various critiques and data to challenge Apellis' claims.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 8, "loop": { "name": "05_the_reveal", "slug": "05-the-reveal", "status": "active", "bestFor": "Product launches, strategic pivots, unexpected findings", "canonId": "019dd956-67e8-77bc-a867-02c2b36370bd", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Setup the Question -> Build Suspense -> The Big Reveal", "description": "Build mystery and anticipation, then deliver a surprising or powerful conclusion", "familyLabel": null }, "matchId": "777dcc74-3c64-4bf9-add4-30634d953462", "evidence": "The document reveals at least 12 cases of vasculitis, contrary to Apellis' claims.", "position": 0, "objective": "What are the actual cases of vasculitis associated with Syfovre?", "confidence": 0.7, "extraction": { "at": "2026-07-16 21:59:16.667257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "analysis", "title": "The slide presents raw FOIA-sourced data tables for specific patient cases.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 1, "textChars": 45, "nDataPoints": 4, "notes": "The slide presents raw FOIA-sourced data tables for specific patient cases.", "elementsJson": [ "data_table" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:38.189+00", "seconds": 2.674, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/9", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-9", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": { "h": 0.84, "w": 0.74, "x": 0.13, "y": 0.1 }, "kind": "table", "text": "Four distinct FDA adverse event report tables", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:38.189+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6b7ffc9b-b8c0-4664-af3c-480dca33773f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 9, "from": 8, "loop": { "name": "05_the_reveal", "slug": "05-the-reveal", "status": "active", "bestFor": "Product launches, strategic pivots, unexpected findings", "canonId": "019dd956-67e8-77bc-a867-02c2b36370bd", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Setup the Question -> Build Suspense -> The Big Reveal", "description": "Build mystery and anticipation, then deliver a surprising or powerful conclusion", "familyLabel": null }, "matchId": "777dcc74-3c64-4bf9-add4-30634d953462", "evidence": "The document reveals at least 12 cases of vasculitis, contrary to Apellis' claims.", "position": 0, "objective": "What are the actual cases of vasculitis associated with Syfovre?", "confidence": 0.7, "extraction": { "at": "2026-07-16 21:59:16.667257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "analysis", "title": "The slide presents raw data from FDA adverse event reports, highlighting specific medical events associated with Syfovre usage.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "sparse", "densityScore": 9, "componentCount": 2, "textChars": 75, "nDataPoints": 3, "notes": "The slide presents raw data from FDA adverse event reports, highlighting specific medical events associated with Syfovre usage.", "elementsJson": [ "data_table" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:38.668+00", "seconds": 3.13, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/10", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-10", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": { "h": 0.68, "w": 0.76, "x": 0.12, "y": 0.09 }, "kind": "table", "text": "Three distinct FOIA adverse event report tables for Syfovre.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:38.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c64d6675-9e83-4099-90ae-71b4e78560f9", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.23, "x": 0.12, "y": 0.03 }, "kind": "title", "text": "Citron Research", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:38.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "825d19a3-194c-4c91-8eb9-58904c1d1b37", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "tension", "title": "Includes two FOIA data tables as evidence of adverse events.", "function": "expose_gap", "rawType": "villain_critique", "block": null, "metadata": { "slideType": "villain_critique", "slideTypeCanon": { "name": "Villain critique", "slug": "villain_critique", "status": "active", "canonId": "019de52d-10bc-7136-bf20-09de59d17447", "version": 1, "description": null }, "function": "expose_gap", "functionCanon": { "name": "Expose gap", "slug": "expose_gap", "status": "active", "canonId": "019de52d-1795-772d-8f3a-75ccfb93fe58", "version": 1, "description": null }, "density": "dense", "densityScore": 73, "componentCount": 10, "textChars": 1419, "nDataPoints": 0, "notes": "Includes two FOIA data tables as evidence of adverse events.", "elementsJson": [ "screenshot", "paragraph", "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:39.494+00", "seconds": 3.766, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/11", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-11", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "The substantial risk of contracting Wet AMD alone warrants an FDA's decision to mandate a warning label for the drug.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:09+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcda-6679594618f3", "parentComponentId": null }, { "bbox": { "h": 0.27, "w": 0.78, "x": 0.11, "y": 0.09 }, "kind": "image", "text": "FOIA data tables", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa3e5a90-a9ea-47a7-9609-ead73348aa6d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.78, "x": 0.11, "y": 0.79 }, "kind": "list", "text": "Benefits...according to Dr. Wykoff: Patients will not see better but Syfovre should slow the progression of the disease.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d6a7d90-0756-4206-bfb6-e64fd854464f", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.78, "x": 0.11, "y": 0.66 }, "kind": "list", "text": "Risks...according to Dr. Wykoff: 20% likelihood of Wet AMD, extended therapy regimen, concerns regarding vasculitis.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "805076cb-24bc-4eb1-b187-32b1b008fadc", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.78, "x": 0.11, "y": 0.88 }, "kind": "paragraph", "text": "The substantial risk of contracting Wet AMD alone warrants an FDA's decision to mandate a warning label for the drug.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4cb23fd8-a0b3-41ab-831e-472bf0ade2c1", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.78, "x": 0.11, "y": 0.49 }, "kind": "paragraph", "text": "In the presentation Dr Wykoff discusses diminution in lesion growth that according to numerous physicians, including Dr. Spaide, is statistically negligible. Despite our respect for Dr. Wykoff's perspective, his commentary would make me afraid to be a shareholder in Apellis.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8609efa3-269c-4d50-bc07-a13a09723d77", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.78, "x": 0.11, "y": 0.42 }, "kind": "paragraph", "text": "As publicized yesterday by Apellis, a presentation was made by Dr. Charles Wykoff on the “Increasing effects of Pegcetacoplan in Gale Study”. This is an add on to the two previous studies.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3eed1b8-5f1b-47ab-af3d-0b18dc8a2f88", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.78, "x": 0.11, "y": 0.58 }, "kind": "quote", "text": "In the real world, I am using pegcetacoplan and I am a believer in anti-complement therapy. I think it's a conversation to be had with each individual patient, what the risk-benefit ratio looks like,", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ef058f1b-cda4-4a8f-a365-b2c8d7aa4d55", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "In the real world, I am using pegcetacoplan and I am a believer in anti-complement therapy. I think it's a conversation to be had with each individual patient, what the risk-benefit ratio looks like, — Dr. Charles Wykoff", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:21:09+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcda-69b1678b01b3", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.65, "x": 0.11, "y": 0.38 }, "kind": "title", "text": "Recent Developments Prove Citron Theory- Gale Study", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:39.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e6bd77d1-bdc0-4801-9e85-ac592c4217e9", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "setup", "title": "Includes a specific reference to a 'Fonzi Scheme' analogy regarding One Reverse Mortgages.", "function": "summarize", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 6, "textChars": 843, "nDataPoints": 1, "notes": "Includes a specific reference to a 'Fonzi Scheme' analogy regarding One Reverse Mortgages.", "elementsJson": [ "paragraph", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:38.535+00", "seconds": 2.801, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/12", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-12", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "In the end, Apellis and Syfovre might have the same fate as Henry Winkler last company he did commercial for, One Reverse Mortgages which ended up getting shut down mired by fraud lawsuits....Just another “Fonzi Scheme”", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-22 23:20:59+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-1ac1-76e9-bcd5-a0677b8513ea", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.764, "x": 0.118, "y": 0.438 }, "kind": "disclaimer", "text": "These reports have been prepared by either Citron Research (\"Citron Research\") or Citron Capital, LLC (\"Citron Capital\")...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:38.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b886525b-d85e-4dd1-9271-59b561f613d6", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.52, "x": 0.118, "y": 0.388 }, "kind": "paragraph", "text": "Cautious Investing To All..............Did somebody say 83%???", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:38.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "16b33a8c-33ea-44b0-b11b-5dab6594b650", "parentComponentId": null }, { "bbox": { "h": 0.055, "w": 0.764, "x": 0.118, "y": 0.145 }, "kind": "paragraph", "text": "It's highly likely that more will emerge about Apellis and Syfovre. Legal action seems imminent, and it won't be surprising if the FDA steps in with a warning label following a more thorough review of the drug.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:38.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "47d47447-5760-4031-b8f2-1377e29cadd9", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.764, "x": 0.118, "y": 0.233 }, "kind": "paragraph", "text": "In the end, Apellis and Syfovre might have the same fate as Henry Winkler last company he did commercial for, One Reverse Mortgages which ended up getting shut down mired by fraud lawsuits....Just another \"Fonzi Scheme\"", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:38.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f812f2d-55ed-48d7-a9b3-ea3f882c83ff", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.115, "x": 0.118, "y": 0.108 }, "kind": "title", "text": "Conclusion", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:38.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35228640-1538-4f0f-8173-c518fcee4d01", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 13, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 12, "name": "The Victory", "beatId": "00cd5a6d-dcee-4fba-90ee-27fb59ffa2f9", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Victory", "slug": "overcoming-monster-the-victory", "status": "active", "canonId": "019dd9b8-3dbe-71b9-b5a9-7191b5f8782b", "version": 1, "description": null }, "evidence": "Citron Research concludes with an expectation of regulatory action, framing it as a victory for their critical stance.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 1, "textChars": 210, "nDataPoints": 0, "notes": null, "elementsJson": [ "paragraph" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:45:37.812+00", "seconds": 2.008, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/13", "deck": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckAnchor": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-13", "deckJson": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json" }, "components": [ { "bbox": { "h": 0.85, "w": 0.76, "x": 0.12, "y": 0.09 }, "kind": "disclaimer", "text": "options, swaps, and other derivatives related to one or more of these securities, and therefore may realize significant gains in the event that the prices of a Covered Issuer's securities decline or appreciate.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:45:37.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "21562363-d339-4a63-bb67-398000abd78f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 13, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 12, "name": "The Victory", "beatId": "00cd5a6d-dcee-4fba-90ee-27fb59ffa2f9", "matchId": "21cb6005-3e14-4d1f-9f20-c078f6b7cc09", "beatType": { "name": "The Victory", "slug": "overcoming-monster-the-victory", "status": "active", "canonId": "019dd9b8-3dbe-71b9-b5a9-7191b5f8782b", "version": 1, "description": null }, "evidence": "Citron Research concludes with an expectation of regulatory action, framing it as a victory for their critical stance.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 13, "from": 1, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "confidence": 0.6, "extraction": { "at": "2026-07-16 21:59:16.706419+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true } ], "arcBeats": [ { "from": 2, "to": 5, "label": "The Monster", "description": "The document presents Syfovre's complications as the central problem to be addressed." }, { "from": 6, "to": 8, "label": "The Struggle", "description": "Citron Research presents various critiques and data to challenge Apellis' claims." }, { "from": 12, "to": 13, "label": "The Victory", "description": "Citron Research concludes with an expectation of regulatory action, framing it as a victory for their critical stance." } ], "loops": [ { "from": 8, "to": 9, "label": "The Reveal", "description": "What are the actual cases of vasculitis associated with Syfovre?" }, { "from": 1, "to": 13, "label": "Cost Of Inaction", "description": "What are the consequences of not taking action against Syfovre's safety concerns?" } ] }